American Society of Hematology--51st annual meeting & exposition. Part 1.
The 51st American Society of Hematology (ASH) Annual Meeting and Exposition, held in New Orleans, included topics covering new therapeutic developments in the field of hematology. This conference report highlights selected presentations on hematological malignancies, lymphoma, Hodgkin lymphoma, AKT inhibitors for the treatment of chronic lymphocytic leukemia, and the activation of GPIb with von Willebrand factor. Investigational drugs discussed include conatumumab (Amgen Inc/Takeda Bio Development Center Ltd) and A-443654 (Abbott Laboratories).
Shumoogam
Jaya
J
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. jaya.shumoogam@thomsonreuters.com
Beecher
Natasher
N
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000503:physiopathology; D008223:Lymphoma / Q000188:drug therapy / Q000503:physiopathology; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D019038:Platelet Glycoprotein GPIb-IX Complex; D014841:von Willebrand Factor